Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

Clinical trial NCT05310344 · UNKNOWN

Trial details

NCT number: NCT05310344
Sponsor: Lei Li
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Carcinoma Platinum-resistant Ovarian Cancer Recurrent Ovarian Carcinoma Albumin-bound Paclitaxel Bevacizumab Survival Outcomes Adverse Events

Start date: 2022-03-27
Primary completion: 2023-03-27
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.